Despite promising candidates for new therapeutic options in the treatment of systemic lupus erythematosus (SLE), many clinical trials have failed in the past few years. The disappointing results have been at least partly be attributed to trial designs. With the aim of stimulating new developments in SLE trial design, an international open space meeting was held on occasion of the European Lupus Meeting 2018 in Duesseldorf, Germany about 'What are the topics you care about for making trials in lupus more effective?'. The Open Space is a participant-driven technology, where the discussion topics and schedule are selected during the meeting by all participants and discussion rounds are led by the people attending encouraging active contributio...
Objective: To assess available evidence on the use of end-points ( outcome measures) in clinical tri...
Multiple clinical trials performed over twenty years in the treatment of rheumatoid arthritis (RA) h...
OBJECTIVE: To assess available evidence on the use of end-points (outcome measures) in clinical t...
Despite promising candidates for new therapeutic options in the treatment of systemic lupus erythema...
Despite promising candidates for new therapeutic options in the treatment of systemic lupus erythema...
Formidable impediments stand in the way of treatment development for lupus. These include the unwiel...
© 2018 Article author(s). Formidable impediments stand in the way of treatment development for lupus...
Objective: Systemic lupus erythematosus (SLE) is a complex multi-organ disease, characterised by rel...
OBJECTIVE: Systemic lupus erythematosus (SLE) is a complex multi-organ disease, characterised by rel...
This review describes eight ‘great ideas’ regarding bench-to-bedside considerations in systemic lupu...
The heterogeneity of lupus poses a signifi cant challenge for clinical trial design. The pleomorphic...
Objective: To assess available evidence on the use of end-points ( outcome measures) in clinical tri...
Objective: To assess available evidence on the use of end-points ( outcome measures) in clinical tri...
Multiple clinical trials performed over twenty years in the treatment of rheumatoid arthritis (RA) h...
OBJECTIVE: To assess available evidence on the use of end-points (outcome measures) in clinical t...
Despite promising candidates for new therapeutic options in the treatment of systemic lupus erythema...
Despite promising candidates for new therapeutic options in the treatment of systemic lupus erythema...
Formidable impediments stand in the way of treatment development for lupus. These include the unwiel...
© 2018 Article author(s). Formidable impediments stand in the way of treatment development for lupus...
Objective: Systemic lupus erythematosus (SLE) is a complex multi-organ disease, characterised by rel...
OBJECTIVE: Systemic lupus erythematosus (SLE) is a complex multi-organ disease, characterised by rel...
This review describes eight ‘great ideas’ regarding bench-to-bedside considerations in systemic lupu...
The heterogeneity of lupus poses a signifi cant challenge for clinical trial design. The pleomorphic...
Objective: To assess available evidence on the use of end-points ( outcome measures) in clinical tri...
Objective: To assess available evidence on the use of end-points ( outcome measures) in clinical tri...
Multiple clinical trials performed over twenty years in the treatment of rheumatoid arthritis (RA) h...
OBJECTIVE: To assess available evidence on the use of end-points (outcome measures) in clinical t...